检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]首都医科大学附属北京天坛医院麻醉科,100050
出 处:《中国医师进修杂志》2011年第12期1-2,共2页Chinese Journal of Postgraduates of Medicine
摘 要:目的 观察服用卡马西平对罗库溴铵作用时效的影响.方法 32例择期行开颅手术患者,ASA分级Ⅰ~Ⅱ级,长期服用卡马西平癫痫患者16例(卡马西平组),未服用卡马西平颅内肿瘤患者16例(非卡马西平组).采用普鲁泊福、瑞芬太尼靶控输注全凭静脉麻醉,单次静脉注射罗库溴铵0.6 mg/kg后,采用四个成串刺激(TOF)加速度法监测肌松情况,记录两组患者罗库溴铵起效时间,肌松恢复至25%、50%、75%时间及肌松恢复指数.结果 两组罗库溴铵起效时间比较差异无统计学意义(P>0.05);卡马西平组肌松恢复至25%、50%、75%时间[分别为(23.9±3.8)、(29.2±4.5)、(36.0±5.4)min]明显短于非卡马西平组[分别为(34.0±2.8)、(40.5±4.6)、(49.9±5.3)min](P<0.01);卡马西平组肌松恢复指数[(12.1±2.9)min]明显短于非卡马西平组[(15.8±3.1)min](P<0.05).结论 服用卡马西平可明显缩短罗库溴铵的临床作用时间和肌松恢复指数,但不影响其起效时间.Objective To study the influence of carbamazepine on the neuromuscular block induced by rocuronium. Methods Thirty-two ASA Ⅰ- Ⅱ patients scheduled for neurosurgical operations were studied: 16 cases suffered from epilepsy were treated with carbamazepine for 24 to 180 months (carbamazepine group); the others suffered from intracranial tumors without antiepileptic treatment (noncarbamazepine group). Anesthesia was induced and maintained with target controlled with propofol 5 μ g/ml was monitored using train-of-four (TOF) stimulation. The onset time and times of muscle relaxation recovery 25%,50%,75% was recorded. Results The onset time was no difference between two groups (P〉0.05),but the times of muscle relaxation recovery 25%, 50%, 75% in carbamazepine group [(23.9±3.8 ), ( 29.2 ±4.5 ), ( 36.0 ± 5.4 ) min] were shorter than those in non-carbamazepine group [( 34.0 ± 2.8 ), (40.5 ± 4.6),( 49.9 ± 5.3 ) min] ( P 〈 0.01 ). The recovery index in carbamazepine group [( 12.1 ± 2.9 ) min] was shorter than that in non-carbamazepine group [(15.8 ± 3.1) min](P〈0.05 ). Conclusion The duration of the rocuronium-induced neuromuscular block is significantly shortened by preceding chronic carbamazepine therapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.30